Cargando…

A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies

BACKGROUND: Phosphatase of regenerating liver-3 (PRL-3) is involved in cellular processes driving metastasis, cell proliferation, invasion, motility and survival. It has been shown to be upregulated and overexpressed in cancer tissue, in contrast to low or no expression in most normal tissue. PRL3-z...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chee, Cheng E., Ooi, Melissa, Lee, Soo-Chin, Sundar, Raghav, Heong, Valerie, Yong, Wei-Peng, Ng, Chin Hin, Wong, Andrea, Lim, Joline S. J., Tan, David S. P., Soo, Ross, Tan, Joshua T. C., Yang, Song, Thura, Min, Al-Aidaroos, Abdul Qader, Chng, Wee Joo, Zeng, Qi, Goh, Boon-Cher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192144/ https://www.ncbi.nlm.nih.gov/pubmed/37060431 http://dx.doi.org/10.1007/s11523-023-00962-w

Ejemplares similares

PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
por: Thura, Min, et al.
Publicado: (2019)

Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
por: Thura, Min, et al.
Publicado: (2021)

PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
por: Thura, Min, et al.
Publicado: (2021)

Author Correction: PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
por: Thura, Min, et al.
Publicado: (2021)

Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody
por: Loh, Amos Hong Pheng, et al.
Publicado: (2023)

Engineering the First Chimeric Antibody in Targeting Intracellular PRL-3 Oncoprotein for Cancer Therapy in Mice
por: Guo, Ke, et al.
Publicado: (2012)

Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia
por: Park, Jung Eun, et al.
Publicado: (2013)

PRL-3 activates mTORC1 in Cancer Progression
por: Ye, Zu, et al.
Publicado: (2015)

PRL-3 suppresses c-Fos and integrin α2 expression in ovarian cancer cells
por: Liu, Hao, et al.
Publicado: (2013)

Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials
por: Loh, Jerold, et al.
Publicado: (2023)

Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
por: Lee, Matilda Xinwei, et al.
Publicado: (2022)

Whole Exome Sequencing of Multi-Regional Biopsies from Metastatic Lesions to Evaluate Actionable Truncal Mutations Using a Single-Pass Percutaneous Technique
por: Heong, Valerie, et al.
Publicado: (2020)

A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours
por: Ang, Yvonne L. E., et al.
Publicado: (2020)

PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types
por: Chia, Pei Ling, et al.
Publicado: (2023)

Recent advances in acute promyelocytic leukaemia
por: Ng, Chin-Hin, et al.
Publicado: (2017)

Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer
por: Radke, I, et al.
Publicado: (2006)

Perceived Social Support Increases Creativity: Experimental Evidence
por: Tan, Chee-Seng, et al.
Publicado: (2022)

A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies
por: Ho, Jingshan, et al.
Publicado: (2022)

PRL-3, a Metastasis Associated Tyrosine Phosphatase, Is Involved in FLT3-ITD Signaling and Implicated in Anti-AML Therapy
por: Zhou, Jianbiao, et al.
Publicado: (2011)

UGT1A6 Polymorphisms Modulated Lung Cancer Risk in a Chinese Population
por: Kua, Ley-Fang, et al.
Publicado: (2012)

A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase
por: Zhou, Jianbiao, et al.
Publicado: (2018)

Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy
por: Sundar, Raghav, et al.
Publicado: (2016)

Neutralising antibody titers and COVID outcomes in cancer patients
por: Lee, Matilda Xinwei, et al.
Publicado: (2023)

Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway
por: Wang, Tingting, et al.
Publicado: (2015)

Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer
por: Ooki, Akira, et al.
Publicado: (2011)

Analysis of molecular determinants of PRL-3
por: Pascaru, Mihaela, et al.
Publicado: (2009)

COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched Controls in Singapore: A Nationwide Cohort Study
por: Tan, Wei Chong, et al.
Publicado: (2023)

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib
por: Wong, Andrea Li Ann, et al.
Publicado: (2015)

Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer
por: Zhao, Joseph J., et al.
Publicado: (2023)

Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer
por: Low, Jia Li, et al.
Publicado: (2021)

Third generation EGFR TKIs: current data and future directions
por: Tan, Chee-Seng, et al.
Publicado: (2018)

Super-enhancers: critical roles and therapeutic targets in hematologic malignancies
por: Jia, Yunlu, et al.
Publicado: (2019)

Real-world assessment of attenuated dosing anti-PD1 therapy as an alternative dosing strategy in a high-income country (as defined by World Bank)
por: Low, Jia Li, et al.
Publicado: (2022)

Src-Mediated Phosphorylation of the Tyrosine Phosphatase PRL-3 Is Required for PRL-3 Promotion of Rho Activation, Motility and Invasion
por: Fiordalisi, James J., et al.
Publicado: (2013)

Depletion of Tissue-Specific Ion Transporters Causes Differential Expression of PRL Targets in Response to Increased Levels of Endogenous PRL
por: Shu, Tingting, et al.
Publicado: (2018)

MiR-130a-3p Inhibits PRL Expression and Is Associated With Heat Stress-Induced PRL Reduction
por: Zhang, Haojie, et al.
Publicado: (2020)

Generation of conditional knockout alleles for PRL-3()
por: Yan, Hong, et al.
Publicado: (2011)

The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia
por: Zhou, Jianbiao, et al.
Publicado: (2012)

Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study
por: Syn, Nicholas Li‐Xun, et al.
Publicado: (2016)

High expression of intratumoral stromal proteins is associated with chemotherapy resistance in breast cancer
por: Wang, Tingting, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nrqm8opnpp31aboknkk3hnmo23